Edgewise Therapeutics, Inc.
EWTX
$44.17
$0.992.29%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 59.03% | 24.58% | 35.06% | 14.23% | 21.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.37% | 17.75% | 22.92% | 15.89% | 11.82% |
| Operating Income | -45.37% | -17.75% | -22.92% | -15.89% | -11.82% |
| Income Before Tax | -58.73% | -20.14% | -26.61% | -19.15% | -14.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.73% | -20.14% | -26.61% | -19.15% | -14.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.73% | -20.14% | -26.61% | -19.15% | -14.66% |
| EBIT | -45.37% | -17.75% | -22.92% | -15.89% | -11.82% |
| EBITDA | -45.89% | -17.89% | -23.33% | -16.15% | -11.85% |
| EPS Basic | -54.72% | -6.69% | -13.14% | -5.96% | -2.17% |
| Normalized Basic EPS | -54.72% | -6.72% | -13.14% | -5.94% | -2.19% |
| EPS Diluted | -54.72% | -6.69% | -13.14% | -5.96% | -2.17% |
| Normalized Diluted EPS | -54.72% | -6.72% | -13.14% | -5.94% | -2.19% |
| Average Basic Shares Outstanding | 2.60% | 12.60% | 11.92% | 12.45% | 12.22% |
| Average Diluted Shares Outstanding | 2.60% | 12.60% | 11.92% | 12.45% | 12.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |